Esperion Therapeutics Inc (NASDAQ:ESPR) Expected to Post Earnings of -$1.85 Per Share

Share on StockTwits

Equities analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to report ($1.85) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Esperion Therapeutics’ earnings. The highest EPS estimate is ($1.66) and the lowest is ($2.04). Esperion Therapeutics reported earnings of ($1.71) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 8.2%. The firm is expected to issue its next earnings results on Thursday, August 1st.

On average, analysts expect that Esperion Therapeutics will report full-year earnings of ($2.10) per share for the current year, with EPS estimates ranging from ($3.01) to ($0.77). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.59) per share, with EPS estimates ranging from ($6.99) to ($0.40). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $2.43. The business had revenue of $145.42 million for the quarter, compared to the consensus estimate of $69.35 million. During the same quarter last year, the firm posted ($1.73) EPS.

Several research firms recently weighed in on ESPR. Stifel Nicolaus reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday. Northland Securities set a $65.00 target price on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Friday. Cowen reiterated a “buy” rating and issued a $85.00 target price on shares of Esperion Therapeutics in a research note on Thursday. BidaskClub cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, June 1st. Finally, Goldman Sachs Group cut shares of Esperion Therapeutics from a “neutral” rating to a “sell” rating and set a $50.00 target price for the company. in a research note on Wednesday, May 29th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $74.45.

In other news, Director Nicole Vitullo sold 15,329 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $44.73, for a total value of $685,666.17. Following the completion of the sale, the director now directly owns 8,319 shares in the company, valued at approximately $372,108.87. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Timothy M. Mayleben acquired 5,000 shares of the stock in a transaction dated Wednesday, March 20th. The stock was acquired at an average price of $43.48 per share, with a total value of $217,400.00. Following the completion of the acquisition, the chief executive officer now owns 56,163 shares in the company, valued at approximately $2,441,967.24. The disclosure for this purchase can be found here. Insiders own 7.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its position in Esperion Therapeutics by 45.2% during the fourth quarter. Rhumbline Advisers now owns 31,583 shares of the biopharmaceutical company’s stock worth $1,453,000 after buying an additional 9,836 shares in the last quarter. BB Biotech AG lifted its holdings in Esperion Therapeutics by 3.4% in the fourth quarter. BB Biotech AG now owns 3,392,964 shares of the biopharmaceutical company’s stock valued at $156,076,000 after acquiring an additional 110,000 shares during the period. Hsbc Holdings PLC acquired a new position in Esperion Therapeutics in the fourth quarter valued at approximately $11,067,000. Bailard Inc. lifted its holdings in Esperion Therapeutics by 561.1% in the first quarter. Bailard Inc. now owns 59,500 shares of the biopharmaceutical company’s stock valued at $2,389,000 after acquiring an additional 50,500 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Esperion Therapeutics in the fourth quarter valued at approximately $203,000.

Shares of NASDAQ ESPR traded up $2.14 during mid-day trading on Monday, hitting $51.31. The company had a trading volume of 420,490 shares, compared to its average volume of 584,658. The firm’s 50-day moving average price is $48.74. Esperion Therapeutics has a 12 month low of $36.06 and a 12 month high of $60.99. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -6.81 and a beta of 1.87.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Read More: How Do You Calculate Return on Equity (ROE)?

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jefferies Financial Group Weighs in on Valero Energy Co.’s Q1 2020 Earnings
Jefferies Financial Group Weighs in on Valero Energy Co.’s Q1 2020 Earnings
Marathon Oil Co. to Post Q4 2019 Earnings of $0.07 Per Share, Jefferies Financial Group Forecasts
Marathon Oil Co. to Post Q4 2019 Earnings of $0.07 Per Share, Jefferies Financial Group Forecasts
Q4 2019 EPS Estimates for CyrusOne Inc Raised by Jefferies Financial Group
Q4 2019 EPS Estimates for CyrusOne Inc Raised by Jefferies Financial Group
Essex Property Trust Inc to Post Q4 2019 Earnings of $3.36 Per Share, Jefferies Financial Group Forecasts
Essex Property Trust Inc to Post Q4 2019 Earnings of $3.36 Per Share, Jefferies Financial Group Forecasts
Analysts Set Expectations for DIGITAL RLTY TR/SH’s Q4 2019 Earnings
Analysts Set Expectations for DIGITAL RLTY TR/SH’s Q4 2019 Earnings
Jefferies Financial Group Weighs in on Simon Property Group Inc’s Q4 2019 Earnings
Jefferies Financial Group Weighs in on Simon Property Group Inc’s Q4 2019 Earnings


© 2006-2019 Ticker Report